有機合成薬品工業 reported an ordinary loss of ¥48 million in its interim results for the fiscal year ending March 2027. The full-year ordinary profit/loss forecast remains unchanged from the previous forecast, with an improvement to ¥500 million expected.
有機合成薬品工業's interim results for the fiscal year ending March 2027 showed an ordinary loss of ¥48 million.
According to the full-year earnings forecast announced on the same day, the ordinary profit/loss forecast remains unchanged from the previous forecast at ¥500 million, representing an expected 65% increase in earnings.
Related stocks include ムトー精工, イサム塗料, サンバイオ and リボミック.